Co-Authors
This is a "connection" page, showing publications co-authored by Mark Espeland and Sally Shumaker.
Connection Strength
1.673
-
Leng X, Espeland MA, Manson JE, Stefanick ML, Gower EW, Hayden KM, Limacher MC, Vaughan L, Robinson J, Wallace R, Wassertheil-Smoller S, Yaffe K, Shumaker SA. Cognitive Function and Changes in Cognitive Function as Predictors of Incident Cardiovascular Disease: The Women's Health Initiative Memory Study. J Gerontol A Biol Sci Med Sci. 2018 05 09; 73(6):779-785.
Score: 0.158
-
Espeland MA, Rapp SR, Manson JE, Goveas JS, Shumaker SA, Hayden KM, Weitlauf JC, Gaussoin SA, Baker LD, Padula CB, Hou L, Resnick SM. Long-term Effects on Cognitive Trajectories of Postmenopausal Hormone Therapy in Two Age Groups. J Gerontol A Biol Sci Med Sci. 2017 Jun 01; 72(6):838-845.
Score: 0.148
-
Driscoll I, Shumaker SA, Snively BM, Margolis KL, Manson JE, Vitolins MZ, Rossom RC, Espeland MA. Relationships Between Caffeine Intake and Risk for Probable Dementia or Global Cognitive Impairment: The Women's Health Initiative Memory Study. J Gerontol A Biol Sci Med Sci. 2016 12; 71(12):1596-1602.
Score: 0.141
-
Beavers DP, Pettinger M, Espeland MA, Snively BM, Leng X, Hunt JR, Tindle HA, Shumaker SA. The Evolution of the WHI 80+ Cohort. J Gerontol A Biol Sci Med Sci. 2016 Mar; 71 Suppl 1:S13-22.
Score: 0.128
-
Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, Vaughan L, Robinson J, Rapp SR, Goveas JS, Wactawski-Wende J, Stefanick ML, Li W, Resnick SM. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med. 2013 Aug 12; 173(15):1429-36.
Score: 0.114
-
Espeland MA, Pettinger M, Falkner KL, Shumaker SA, Limacher M, Thomas F, Weaver KE, Stefanick ML, McQuellon C, Hunt JR, Johnson KC. Demographic and health factors associated with enrollment in posttrial studies: the Women's Health Initiative Hormone Therapy Trials. Clin Trials. 2013; 10(3):463-72.
Score: 0.111
-
Casanova R, Whitlow CT, Wagner B, Williamson J, Shumaker SA, Maldjian JA, Espeland MA. High dimensional classification of structural MRI Alzheimer's disease data based on large scale regularization. Front Neuroinform. 2011; 5:22.
Score: 0.100
-
Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, Coker LH, Gaussoin SA, Stefanick ML, Lane DS, Maki PM, Resnick SM. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health (Larchmt). 2010 Mar; 19(3):371-9.
Score: 0.090
-
Coker LH, Espeland MA, Rapp SR, Legault C, Resnick SM, Hogan P, Gaussoin S, Dailey M, Shumaker SA. Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS). J Steroid Biochem Mol Biol. 2010 Feb 28; 118(4-5):304-10.
Score: 0.088
-
Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004 Jun 23; 291(24):2959-68.
Score: 0.060
-
Resnick SM, Coker LH, Maki PM, Rapp SR, Espeland MA, Shumaker SA. The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clin Trials. 2004; 1(5):440-50.
Score: 0.058
-
Younan D, Wang X, Casanova R, Barnard R, Gaussoin SA, Saldana S, Petkus AJ, Beavers DP, Resnick SM, Manson JE, Serre ML, Vizuete W, Henderson VW, Sachs BC, Salinas JA, Gatz M, Espeland MA, Chui HC, Shumaker SA, Rapp SR, Chen JC. PM2.5 associated with gray matter atrophy reflecting increased Alzheimers risk in older women. Neurology. 2020 11 18.
Score: 0.047
-
Younan D, Petkus AJ, Widaman KF, Wang X, Casanova R, Espeland MA, Gatz M, Henderson VW, Manson JE, Rapp SR, Sachs BC, Serre ML, Gaussoin SA, Barnard R, Saldana S, Vizuete W, Beavers DP, Salinas JA, Chui HC, Resnick SM, Shumaker SA, Chen JC. Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer's disease. Brain. 2020 01 01; 143(1):289-302.
Score: 0.044
-
Baker LD, Rapp SR, Shumaker SA, Manson JE, Sesso HD, Gaussoin SA, Harris D, Caudle B, Pleasants D, Espeland MA. Design and baseline characteristics of the cocoa supplement and multivitamin outcomes study for the Mind: COSMOS-Mind. Contemp Clin Trials. 2019 08; 83:57-63.
Score: 0.043
-
Gaussoin SA, Espeland MA, Beavers DP, Casanova R, Garcia KR, Snively BM, Shumaker SA, Wallace RB, Rapp SR. Dementia outcomes after addition of proxy-based assessments for deceased or proxy-dependent participants. Int J Geriatr Psychiatry. 2019 10; 34(10):1403-1411.
Score: 0.042
-
Petkus AJ, Resnick SM, Rapp SR, Espeland MA, Gatz M, Widaman KF, Wang X, Younan D, Casanova R, Chui H, Barnard RT, Gaussoin S, Goveas JS, Hayden KM, Henderson VW, Sachs BC, Saldana S, Shadyab AH, Shumaker SA, Chen JC. General and domain-specific cognitive reserve, mild cognitive impairment, and dementia risk in older women. Alzheimers Dement (N Y). 2019; 5:118-128.
Score: 0.042
-
Driscoll I, Snively BM, Espeland MA, Shumaker SA, Rapp SR, Goveas JS, Casanova RL, Wactawski-Wende J, Manson JE, Rossom R, Brooks J, Hernandez DG, Singleton AB, Resnick SM. A candidate gene study of risk for dementia in older, postmenopausal women: Results from the Women's Health Initiative Memory Study. Int J Geriatr Psychiatry. 2019 05; 34(5):692-699.
Score: 0.042
-
Korthauer LE, Goveas J, Espeland MA, Shumaker SA, Garcia KR, Tindle H, Salmoirago-Blotcher E, Sink KM, Vaughan L, Rapp SR, Resnick SM, Driscoll I. Negative Affect Is Associated With Higher Risk of Incident Cognitive Impairment in Nondepressed Postmenopausal Women. J Gerontol A Biol Sci Med Sci. 2018 03 14; 73(4):506-512.
Score: 0.039
-
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017 09 12; 318(10):927-938.
Score: 0.038
-
Coker LH, Espeland MA, Hogan PE, Resnick SM, Bryan RN, Robinson JG, Goveas JS, Davatzikos C, Kuller LH, Williamson JD, Bushnell CD, Shumaker SA. Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies. Neurology. 2014 Feb 04; 82(5):427-34.
Score: 0.029
-
Vaughan L, Espeland MA, Snively B, Shumaker SA, Rapp SR, Shupe J, Robinson JG, Sarto GE, Resnick SM. The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). Brain Res. 2013 Jun 13; 1514:3-11.
Score: 0.028
-
Rapp SR, Legault C, Espeland MA, Resnick SM, Hogan PE, Coker LH, Dailey M, Shumaker SA. Validation of a cognitive assessment battery administered over the telephone. J Am Geriatr Soc. 2012 Sep; 60(9):1616-23.
Score: 0.027
-
Legault C, Jennings JM, Katula JA, Dagenbach D, Gaussoin SA, Sink KM, Rapp SR, Rejeski WJ, Shumaker SA, Espeland MA. Designing clinical trials for assessing the effects of cognitive training and physical activity interventions on cognitive outcomes: the Seniors Health and Activity Research Program Pilot (SHARP-P) study, a randomized controlled trial. BMC Geriatr. 2011 May 26; 11:27.
Score: 0.024
-
Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, Granek IA, Hogan P, Ockene JK, Shumaker SA. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006 May; 91(5):1802-10.
Score: 0.017
-
Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003 May 28; 289(20):2663-72.
Score: 0.014